Bristol Myers Squibb (CELG-RI) EBT Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly EBT Margin of 31.5% for Q2 2026, up 1705.0% year-over-year from 1.74% in Q2 2025, and up 11.69% quarter-over-quarter from 28.2% in Q1 2026.
Bristol Myers Squibb (CELG-RI) EBT Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported EBT Margin for 18 consecutive years, with 31.5% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT Margin rose 1705.0% year-over-year to 31.5%; the TTM figure through Jun 2026 stood at 24.21% (up 1039.0% YoY), while the FY2025 annual figure was 19.36%, up 3670.0% from the prior year.
- EBT Margin improved to 31.5% in Q2 2026 per CELG-RI's latest filing, from 28.2% in the prior quarter.
- Across five years, EBT Margin topped out at 31.5% in Q2 2026 and bottomed at 97.06% in Q1 2024.
- Historically, EBT Margin has averaged 11.61% across 5 years, with a median of 16.39% in 2022.
- Annual changes were most pronounced in 2024 — EBT Margin sank 12149 bps — and 2025, when it soared 12358 bps.
- Bristol Myers Squibb's EBT Margin stood at 16.3% in 2022, then dropped by 11 bps to 14.59% in 2023, then tumbled by 90 bps to 1.42% in 2024, then jumped by 729 bps to 11.76% in 2025, then jumped by 168 bps to 31.5% in 2026.
- Business Quant data shows CELG-RI's EBT Margin at 31.5% in Q2 2026, 28.2% in Q1 2026, and 11.76% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 29.63% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 18.19% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 27.53% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -131.41% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -4.34% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 4.21% |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 31.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.50% |
| Mar 31, 2026 | 28.20% |
| Dec 31, 2025 | 11.76% |
| Sep 30, 2025 | 25.48% |
| Jun 30, 2025 | 14.45% |
| Mar 31, 2025 | 26.52% |
| Dec 31, 2024 | 1.42% |
| Sep 30, 2024 | 14.09% |
| Jun 30, 2024 | 10.54% |
| Mar 31, 2024 | -97.06% |
| Dec 31, 2023 | 14.59% |
| Sep 30, 2023 | 19.49% |
| Jun 30, 2023 | 16.56% |
| Mar 31, 2023 | 24.43% |
| Dec 31, 2022 | 16.30% |
| Sep 30, 2022 | 19.69% |
| Jun 30, 2022 | 16.47% |
| Mar 31, 2022 | 14.48% |
| Dec 31, 2021 | 15.50% |
| Sep 30, 2021 | 18.56% |